Healthcare provider profile · identity verified

Amjad Shahid, MD

Internal Medicine · MAPLEWOOD, MN · NPI 1326071101

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	607	183
Lisinopril	Lisinopril	409	116
Amlodipine Besylate	Amlodipine Besylate	367	105
Losartan Potassium	Losartan Potassium	299	88
Simvastatin	Simvastatin	283	73
Levothyroxine Sodium	Levothyroxine Sodium	242	70
Omeprazole	Omeprazole	236	79
Tamsulosin Hcl	Tamsulosin Hcl	228	69
Metformin Hcl	Metformin Hcl	211	65
Hydrochlorothiazide	Hydrochlorothiazide	176	52
Gabapentin	Gabapentin	169	62
Metoprolol Succinate	Metoprolol Succinate	164	49
Trazodone Hcl	Trazodone Hcl	135	52
Glimepiride	Glimepiride	116	38
Warfarin Sodium	Warfarin Sodium	114	22
Pantoprazole Sodium	Pantoprazole Sodium	112	37
Sertraline Hcl	Sertraline Hcl	112	31
Furosemide	Furosemide	105	37
Rosuvastatin Calcium	Rosuvastatin Calcium	103	34
Allopurinol	Allopurinol	101	34
Metoprolol Tartrate	Metoprolol Tartrate	99	31
Albuterol Sulfate Hfa	Albuterol Sulfate	85	39
Atenolol	Atenolol	75	23
Metformin Hcl Er	Metformin Hcl	74	18
Fluticasone Propionate	Fluticasone Propionate	68	25
Azithromycin	Azithromycin	63	55
Potassium Chloride	Potassium Chloride	57	24
Jardiance	Empagliflozin	55	16
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	55	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	53	15
Mirtazapine	Mirtazapine	48	11
Triamcinolone Acetonide	Triamcinolone Acetonide	47	32
Citalopram Hbr	Citalopram Hydrobromide	46	13
Pravastatin Sodium	Pravastatin Sodium	45	14
Ezetimibe	Ezetimibe	43	15
Tizanidine Hcl	Tizanidine Hcl	42	20
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	42	13
Famotidine	Famotidine	40	13
Sumatriptan Succinate	Sumatriptan Succinate	40	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	39	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	39	11
Oxybutynin Chloride Er	Oxybutynin Chloride	39	11
Finasteride	Finasteride	37	11
Glipizide	Glipizide	37	11
Meloxicam	Meloxicam	37	16
Glipizide Er	Glipizide	36	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	32	suppressed
Montelukast Sodium	Montelukast Sodium	32	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	32	suppressed
Prednisone	Prednisone	31	26
Ozempic	Semaglutide	30	suppressed
Carvedilol	Carvedilol	29	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	28	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	28	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	27	suppressed
Buspirone Hcl	Buspirone Hcl	26	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	15
Nystatin	Nystatin	24	13
Alendronate Sodium	Alendronate Sodium	22	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	22	suppressed
Hydrocortisone	Hydrocortisone	22	suppressed
Solifenacin Succinate	Solifenacin Succinate	22	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	21	suppressed
Azelastine Hcl	Azelastine Hcl	20	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Ventolin Hfa	Albuterol Sulfate	20	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Hydralazine Hcl	Hydralazine Hcl	19	suppressed
Januvia	Sitagliptin Phosphate	19	suppressed
Klor-Con M20	Potassium Chloride	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Terazosin Hcl	Terazosin Hcl	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	17	suppressed
Baclofen	Baclofen	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Estradiol	Estradiol	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Amoxicillin	Amoxicillin	15	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	15	suppressed
Celecoxib	Celecoxib	15	suppressed
Cephalexin	Cephalexin	15	15
Eliquis	Apixaban	15	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	14	suppressed
Lorazepam	Lorazepam	14	suppressed
Mupirocin	Mupirocin	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Easy Touch Pen Needle	Pen Needle, Diabetic	13	suppressed
Gemfibrozil	Gemfibrozil	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Tiadylt Er	Diltiazem Hcl	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	12	11
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Spiriva Handihaler	Tiotropium Bromide	12	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	12	suppressed
Bromocriptine Mesylate	Bromocriptine Mesylate	11	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Klor-Con	Potassium Chloride	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Tretinoin	Tretinoin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error